Â鶹ӰԺ

Arpeggio Bio, a preclinical company whose technology provides a mechanistic understanding of how drugs work, today announced that it has closed a $3.2 million seed financing round, which was oversubscribed by over $2 million. Funding will support

After years of companies being sold off or growing and relocating, Â鶹ӰԺ’s life-sciences sector is showing signs of reaching critical mass.Companies such as Clovis Oncology Inc. (Nasdaq: CLVS), SomaLogic Inc., Array Biopharma Inc. (Nasdaq: ARRY)